Clinical Trial Update: Safety and Immune Response of Novartis MenACWY-CRM Conjugate Vaccine When Given to Healthy Toddlers [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the safety and immune response of the MenACWY-CRM meningococcal conjugate vaccine in healthy toddlers; results completed and posted in …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenACWY-CRM Conjugate Vaccine (Menveo) (Meningococcal conjugate vaccine (A, C, W, Y) using CRM197)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Infections | Phase 3 | Status: COMPLETED | Results posted: 2013-03-15